Hemeoxygenase-1 in thyroid cancer progression

ALONSO EG; PICHEL P; MASCARÓ M.; FERNÁNDEZ CHÁVEZ L; PEROS I; SCHWEITZER K; COLÓ GP; RECIO S; CARBALLIDO JA; ARÉVALO J; CASTELLANO L.; FACCHINETTI MM; GANDINI NA.; CURINO AC

Jornada; SAIC Sociedad Argentina de Investigación Clínica; 2020

Previous work from our group shows that Hemeoxygenase-1 (HO-1) is overexpressed in several types of tumor and the enzyme can be located in cell cytoplasm and/or nucleus. This subcellular distribution is caused by the cleavage of the C-terminus of HO-1 by calpain 1 (CAPN1), calpain 2 (CAPN2), cathepsin B (CTSB) and signal peptide peptidase (SPP). In thyroid cancer (TC), HO-1 potential utility as biomarker remains underexplored. The aim of this work was to study HO-1 expression in TC and its correlation with clinical-pathological data. Tumor biopsies (N=64) and fine needle aspiration biopsies (FNAB) (N=22) were used to asses HO- 1 expression by inmunohistochemistry (IHC) and inmunocytochemistry (ICC), respectively. In addition, mRNA expression of HO-1, CAPN1, CAPN2, CTSB and SPP were analyzed by using GEPIA2 and Kaplan-Meier Plotter databases in in silico assays. In TC biopsies, overexpression (OE) of HO-1 by IHC was found in the tumor (T) respect to non-malignant areas to the tumor (NMT) (Mann Whitney test, p